These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11992769)

  • 1. Design and synthesis of a piperazinylalkylisoxazole library for subtype selective dopamine receptor ligands.
    Cha MY; Choi BC; Kang KH; Pae AN; Choi KI; Cho YS; Koh HY; Lee HY; Jung D; Kong JY
    Bioorg Med Chem Lett; 2002 May; 12(10):1327-30. PubMed ID: 11992769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype.
    Robarge MJ; Husbands SM; Kieltyka A; Brodbeck R; Thurkauf A; Newman AH
    J Med Chem; 2001 Sep; 44(19):3175-86. PubMed ID: 11543687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QSAR studies on piperazinylalkylisoxazole analogues selectively acting on dopamine D3 receptor by HQSAR and CoMFA.
    Cha MY; Lee IY; Cha JH; Choi KI; Cho YS; Koh HY; Pae AN
    Bioorg Med Chem; 2003 Apr; 11(7):1293-8. PubMed ID: 12628656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenylpiperazinylmethylheterocycle derivatives: synthesis and dopamine receptor binding profiles.
    Abadi AH
    Arch Pharm (Weinheim); 2004 Jul; 337(7):383-90. PubMed ID: 15237388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D2, D3, and D4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding.
    Ehrlich K; Götz A; Bollinger S; Tschammer N; Bettinetti L; Härterich S; Hübner H; Lanig H; Gmeiner P
    J Med Chem; 2009 Aug; 52(15):4923-35. PubMed ID: 19606869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors.
    Hidaka K; Tada S; Matsumoto M; Ohmori J; Tasaki Y; Nomura T; Usuda S; Yamaguchi T
    Br J Pharmacol; 1996 Apr; 117(8):1625-32. PubMed ID: 8732269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
    Mierau J; Schneider FJ; Ensinger HA; Chio CL; Lajiness ME; Huff RM
    Eur J Pharmacol; 1995 Jun; 290(1):29-36. PubMed ID: 7664822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of structurally constrained hybrid analogues containing ropinirole moiety as a novel class of potent and selective dopamine D3 receptor ligands.
    Zhou B; Hong KH; Ji M; Cai J
    Chem Biol Drug Des; 2018 Sep; 92(3):1597-1609. PubMed ID: 29710404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and evaluation of chromen-2-ones as potent and selective human dopamine D4 antagonists.
    Kesten SR; Heffner TG; Johnson SJ; Pugsley TA; Wright JL; Wise LD
    J Med Chem; 1999 Sep; 42(18):3718-25. PubMed ID: 10479303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of binding of [3H]PD 128907, a selective dopamine D3 receptor agonist ligand, to CHO-K1 cells.
    Akunne HC; Towers P; Ellis GJ; Dijkstra D; Wikström H; Heffner TG; Wise LD; Pugsley TA
    Life Sci; 1995; 57(15):1401-10. PubMed ID: 7674830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
    Ohmori J; Maeno K; Hidaka K; Nakato K; Matsumoto M; Tada S; Hattori H; Sakamoto S; Tsukamoto S; Usuda S; Mase T
    J Med Chem; 1996 Jul; 39(14):2764-72. PubMed ID: 8709107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist.
    Nakane M; Cowart MD; Hsieh GC; Miller L; Uchic ME; Chang R; Terranova MA; Donnelly-Roberts DL; Namovic MT; Miller TR; Wetter JM; Marsh K; Stewart AO; Brioni JD; Moreland RB
    Neuropharmacology; 2005 Jul; 49(1):112-21. PubMed ID: 15992586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, lipophilic properties, and binding affinities of potential ligands in positron emission tomography (PET) for visualization of brain dopamine D4 receptors.
    Lacivita E; De Giorgio P; Colabufo NA; Berardi F; Perrone R; Niso M; Leopoldo M
    Chem Biodivers; 2014 Feb; 11(2):299-310. PubMed ID: 24591318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
    Millan MJ; Peglion JL; Vian J; Rivet JM; Brocco M; Gobert A; Newman-Tancredi A; Dacquet C; Bervoets K; Girardon S
    J Pharmacol Exp Ther; 1995 Nov; 275(2):885-98. PubMed ID: 7473180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats.
    Millan MJ; Audinot V; Rivet JM; Gobert A; Vian J; Prost JF; Spedding M; Peglion JL
    Eur J Pharmacol; 1994 Aug; 260(2-3):R3-5. PubMed ID: 7988633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [3H] A-369508 ([2-[4-(2-cyanophenyl)-1-piperazinyl]-N-(3-methylphenyl) acetamide): an agonist radioligand selective for the dopamine D4 receptor.
    Moreland RB; Terranova MA; Chang R; Uchic ME; Matulenko MA; Surber BW; Stewart AO; Brioni JD
    Eur J Pharmacol; 2004 Aug; 497(2):147-54. PubMed ID: 15306199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2,4-Disubstituted pyrroles: synthesis, traceless linking and pharmacological investigations leading to the dopamine D4 receptor partial agonist FAUC 356.
    Bergauer M; Hübner H; Gmeiner P
    Bioorg Med Chem Lett; 2002 Aug; 12(15):1937-40. PubMed ID: 12113813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action.
    Biswas S; Zhang S; Fernandez F; Ghosh B; Zhen J; Kuzhikandathil E; Reith ME; Dutta AK
    J Med Chem; 2008 Jan; 51(1):101-17. PubMed ID: 18072730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.